Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Clinical trial NCT04613596 · RECRUITING

Trial details

NCT number: NCT04613596
Sponsor: Mirati Therapeutics Inc.
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Advanced Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer

Start date: 2020-12-02
Primary completion: 2028-10-31
Enrollment: 626

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.